Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. - Test2 - elhamkhani - TriplyDB

Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.

Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.

http://www.wikidata.org/entity/Q33346685

about

Emerging drugs for uveitis Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study.Cyclophosphamide for ocular inflammatory diseases Cyclosporine for ocular inflammatory diseases.Mycophenolate mofetil for ocular inflammation.Pharmacotherapy for uveitis: current management and emerging therapy.Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.Success with single-agent immunosuppression for multifocal choroidopathies.Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device.Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review.Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis.Corticosteroid-sparing therapy: practice patterns among uveitis specialists Remission of Intermediate Uveitis: Incidence and Predictive Factors Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Tr Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.Systemic lupus erythematosus, pregnancy and carcinoma of the tongue.Methotrexate for ocular inflammatory diseases.Azathioprine for ocular inflammatory diseases.Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease.Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys.Squamous cell carcinoma on the palate in a patient with systemic lupus erythematosus: case report and review of literature.Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis.A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I.Side-effects of anti-inflammatory therapy in uveitis.Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues.Pharmacologic Treatment of Noninfectious Uveitis.Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner.Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention.Treatment of uveitis: beyond steroids.Immunosuppression for the Uveitides.Recurrence of uveitis after discontinuation of infliximab.[DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].[Anti-TNF-α treatment for uveitis. Analysis of the current situation].Efficacy and adverse reactions of methotrexate in the treatment of ocular cicatricial pemphigoid: A case series study

P2860

Q24630848-B7F42029-BA01-4B5D-BB12-70249D294443 Q26752297-E88FE934-7CBA-4B2C-AF6E-988CD8F76744 Q27693189-593A451E-B086-4268-AE09-38436E177716 Q33478325-42DB353F-3401-4F6E-B04D-A17BCB25FD12 Q33517496-7FD052FC-67AD-4E6F-B841-44362474A798 Q33520584-7106E5B7-3729-49FB-9D28-3F5B881D5FE2 Q33521396-2C436475-7C0A-43C1-9BFB-C18E9777AFD8 Q34274075-6A2B4092-B15D-4F85-8C6E-4E4328721638 Q34444734-6A9C5DCE-73EE-4E15-A145-1BCD482F0080 Q34623981-02A596BF-5A8A-4386-9C23-0A090B46BD5E Q34630641-FEC6E51A-826E-4E4A-9DDD-C0650D9214C9 Q35176767-D0B5624C-B48E-45F6-8915-1F5177763D90 Q35215459-588DA463-EDAC-4754-B319-FAFDF72C95DD Q35221140-41C5933D-F9C3-4B08-B135-791048E1C321 Q35233322-276730DB-474C-4666-BAC2-165B41DB7F9E Q35828102-423048A6-C733-4538-96BD-E1787D356877 Q35895632-956C6188-C854-4620-A94E-DEE32F51BD9B Q36090279-74F2F7AD-AD7F-49CE-8198-376BF58C8A19 Q36174993-AD12AF46-9B27-4096-A941-CB2794C17E64 Q36893850-907E936D-F0E1-4132-9B9F-E868BF2EAE44 Q37204512-C43800B9-5765-4AD6-A67D-D3A00E9DECF3 Q37366679-5AF50B9B-0D66-4CEB-854F-957AAB68310F Q37406600-691D57A3-EB59-4F17-B722-25EDF6029542 Q37692472-1A855BD7-A05E-4E8E-8162-9F6F95722BAD Q37819551-B7554675-3070-4FD1-854C-CC53630F474A Q37956187-6918CE57-ABAC-4C14-AE71-D59742001639 Q38184630-75DFA5E1-41DB-44C6-B7E4-14C4BE7D3A30 Q38250103-A3C1685A-4234-4093-9A83-AF5BDDE3E1BC Q38250116-DCB7CA9A-C7E1-4D63-9C52-EF5F112E6B9B Q38261127-DCF2D4AA-D5FD-4276-8593-50722FD027AB Q38464355-B3054A1D-EEB8-4F3B-94C5-B8190A0AD301 Q40450258-091F6221-4617-420C-8D50-3BFB06165C15 Q42292365-3194A549-6FE3-4372-8345-2F6D6E4E73C0 Q42359937-5CC912CB-F4D3-4E7B-8D5B-6BA28D6293C8 Q42867486-1DA95ACC-B423-4D52-817E-EDBBF1FA5915 Q47932596-3C733039-BB9E-4CCC-9C33-2D85F833AA41 Q47959278-B0C465E0-2EB4-44E3-9A12-ECA22A761F25 Q49845401-46A1B8CA-4B31-4AE8-A5E8-1820C645E056 Q52899661-17D25A4E-0C89-4253-B3C0-E8227DEF9C0A Q58704407-12139784-CE5C-4960-A099-E1831501FC76

P2860

Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.

http://www.wikidata.org/entity/Q33346685

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Long-term risk of malignancy a ...... al assessment of the evidence.

@ast

Long-term risk of malignancy a ...... al assessment of the evidence.

@en

type

label

Long-term risk of malignancy a ...... al assessment of the evidence.

@ast

Long-term risk of malignancy a ...... al assessment of the evidence.

@en

prefLabel

Long-term risk of malignancy a ...... al assessment of the evidence.

@ast

Long-term risk of malignancy a ...... al assessment of the evidence.

@en

P1433

Q33346685-6E79A37B-4A5C-45F8-A732-7B6531AED08E

P1476

Q33346685-ECFE3D0D-5F78-4D38-A1C6-91BC8B9DD676

P2093

Q33346685-3117128F-171C-4836-B528-5A163FA497ED

Q33346685-6B3A2692-09CF-4E82-B993-3C28973D3C1D

Q33346685-6EFA4D63-ECE6-488A-9A0A-FF1DC4A9994A

Q33346685-74B9A9DA-B0AF-495E-97F0-8A39B49B18A4

Q33346685-7F5E4E26-15F7-4B6D-9933-248819C42575

Q33346685-9C1711DD-74B3-4E77-A7BD-7ABDA20B64B7

Q33346685-A27242D8-42D7-4755-96EB-718B2020413A

Q33346685-B2EEF0C7-18FE-4472-93B1-EEA6D5C518A6

P2860

Q33346685-02E5429A-E86F-4BA9-8893-391D43103E78

Q33346685-093EE143-E4A9-4B15-ABF6-808124C25712

Q33346685-0A48D5BB-6CB1-479F-8A10-97CB663944A1

Q33346685-137BD9ED-CB96-4F36-B786-9533E6FDE747

Q33346685-17E0A5D0-7F4B-4951-A53F-34263B2096D4

Q33346685-181AF27B-7061-4270-9C10-101A4635F4DC

Q33346685-1AF0D109-ABC8-489B-A57D-4525CA50458A

Q33346685-1DD41EAB-4486-4403-B39C-5C844D0B78B4

Q33346685-1E5F8C75-FEC0-47F9-810E-D79AF1C05D47

Q33346685-1EE9D72A-7C37-4E24-B7E5-9D5A459879D0

P304

Q33346685-316DB3D5-9114-486E-B196-2C6127E25E07

P31

Q33346685-8AF0CCB7-CA73-43F9-B4DE-962B7B81A342

P356

Q33346685-A6B2C021-CEEF-433C-8BAD-A244608D6484

P407

Q33346685-72443BD5-E3E5-4A7D-96A1-98A87C4AD960

P433

Q33346685-9E999540-6A70-4974-BB83-86349C49EE06

P478

Q33346685-F8173DA2-4238-4BF2-892F-CC14484E65CA

P50

Q33346685-2AAD9BDD-84B2-41C8-A607-E79342751653

Q33346685-2B23BD9E-E1DF-46B5-9F50-60D481FC0B20

Q33346685-3A047B89-6449-4D2F-A9B4-1983E89C6ECC

P577

Q33346685-1B58E593-3788-42D3-BB7B-0EF92425C4B3

P5875

Q33346685-DBAB1DF8-03DF-4DBF-B15A-3BF96F4F2389

P698

Q33346685-D4A60695-9E9F-46B7-B825-69B01901F2F4

P921

Q33346685-63330EC5-F1D1-454B-9E84-83E908EB7BA3

P932

Q33346685-C3BD9112-C591-496B-A8A8-F11B6F916934

P356

J.AJO.2008.04.035

P1433

American Journal of Ophthalmology

P1476

Long-term risk of malignancy a ...... al assessment of the evidence.

@en

P2093

C Stephen Foster

http://www.w3.org/2001/XMLSchema#string

Douglas A Jabs

http://www.w3.org/2001/XMLSchema#string

Eric B Suhler

http://www.w3.org/2001/XMLSchema#string

James T Rosenbaum

http://www.w3.org/2001/XMLSchema#string

Jennifer E Thorne

http://www.w3.org/2001/XMLSchema#string

John H Kempen

http://www.w3.org/2001/XMLSchema#string

Kathy J Helzlsouer

http://www.w3.org/2001/XMLSchema#string

Sapna Gangaputra

http://www.w3.org/2001/XMLSchema#string

P2860

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy

Atherosclerosis — An Inflammatory Disease

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

The incidence of bladder cancer after cyclophosphamide therapy

Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation

Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up.

Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients.

P304

802-12.e1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJO.2008.04.035

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

146

http://www.w3.org/2001/XMLSchema#string

P50

Robert B Nussenblatt

Grace A Levy-Clarke

P577

2008-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5277321

http://www.w3.org/2001/XMLSchema#string

P698

18579112

http://www.w3.org/2001/XMLSchema#string

P921

P932

2614443

http://www.w3.org/2001/XMLSchema#string